These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 17239496

  • 1. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.
    Vaccine; 2007 Mar 01; 25(11):2001-10. PubMed ID: 17239496
    [Abstract] [Full Text] [Related]

  • 2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    Virology; 2007 Feb 20; 358(2):266-72. PubMed ID: 17010405
    [Abstract] [Full Text] [Related]

  • 3. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines.
    Schellenbacher C, Roden R, Kirnbauer R.
    J Virol; 2009 Oct 20; 83(19):10085-95. PubMed ID: 19640991
    [Abstract] [Full Text] [Related]

  • 4. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.
    Vaccine; 2015 Oct 13; 33(42):5553-5563. PubMed ID: 26382603
    [Abstract] [Full Text] [Related]

  • 7. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X, Zhang T, Liu H, Hao Y, Liao G, Xu X.
    Hum Vaccin Immunother; 2018 Oct 13; 14(8):2025-2033. PubMed ID: 29683766
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M, Tumban E, Dziduszko A, Ozbun MA, Peabody DS, Chackerian B.
    Vaccine; 2014 Jul 23; 32(34):4267-74. PubMed ID: 24962748
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.
    Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, Faust H, Dillner J, Roden RBS, Kirnbauer R.
    J Invest Dermatol; 2013 Dec 23; 133(12):2706-2713. PubMed ID: 23752042
    [Abstract] [Full Text] [Related]

  • 14. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E, Peabody J, Peabody DS, Chackerian B.
    PLoS One; 2011 Dec 23; 6(8):e23310. PubMed ID: 21858066
    [Abstract] [Full Text] [Related]

  • 15. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 16. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R.
    PLoS One; 2017 Mar 02; 12(1):e0169533. PubMed ID: 28056100
    [Abstract] [Full Text] [Related]

  • 17. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.
    Virol J; 2015 Sep 11; 12():140. PubMed ID: 26362430
    [Abstract] [Full Text] [Related]

  • 18. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.
    Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, Poo H.
    Vaccine; 2012 May 09; 30(22):3286-94. PubMed ID: 22426329
    [Abstract] [Full Text] [Related]

  • 19. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P, Matsui K, Wong M, Alvarez J, Lambert P, Christensen ND, Hu J, Huber B, Kirnbauer R, Wang JW, Roden RBS.
    J Virol; 2022 Jul 13; 96(13):e0056622. PubMed ID: 35703545
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.